Cost-effectiveness of drotrecogin alfa (activated) in treating severe sepsis in the UK

被引：0
|
作者：
Davies, A
Hutton, J
Ridley, S
Chinn, C
Barber, B
机构：
来源：
INTENSIVE CARE MEDICINE | 2002年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
623
引用
收藏
页码：S161 / S161
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of drotrecogin alfa (activated) in treating severe sepsis in Sweden
    Hjelmgren, J
    Ragnarson, TG
    Persson, U
    Davis, A
    Finnern, HW
    Myren, KJ
    [J]. INTENSIVE CARE MEDICINE, 2003, 29 : S94 - S94
  • [2] Cost-effectiveness of drotrecogin alfa (activated) (Xigris™) in severe sepsis
    Angus, DC
    Linde-Zwirble, WT
    Clermont, G
    Ball, DE
    Basson, BR
    Ely, EW
    Laterre, PF
    Vincent, JL
    Bernard, GR
    van Hout, B
    [J]. CRITICAL CARE MEDICINE, 2002, 30 (02) : 493 - 493
  • [3] Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis
    Angus, DC
    Linde-Zwirble, WT
    Clermont, G
    Ball, DE
    Basson, BR
    Ely, EW
    Laterre, PF
    Vincent, JL
    Bernard, G
    van Hout, B
    [J]. CRITICAL CARE MEDICINE, 2003, 31 (01) : 1 - 11
  • [4] Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany
    Neilson, AR
    Burchardi, H
    Chinn, C
    Clouth, J
    Schneider, H
    Angus, D
    [J]. JOURNAL OF CRITICAL CARE, 2003, 18 (04) : 217 - 227
  • [5] Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany
    Neilson, AR
    Schneider, H
    Chinn, C
    Clouth, J
    Burchardi, H
    [J]. INTENSIVE CARE MEDICINE, 2002, 28 : S161 - S161
  • [6] Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis in Spain
    Sacristán, JA
    Prieto, L
    Huete, T
    Artigas, A
    Badia, X
    Chinn, C
    Hudson, P
    [J]. VALUE IN HEALTH, 2002, 5 (06) : 562 - 562
  • [7] Treating severe sepsis with drotrecogin alfa (activated)
    Wyncoll, D
    [J]. HOSPITAL MEDICINE, 2003, 64 (03): : 168 - 172
  • [8] Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure
    França, LR
    Launois, R
    Le Lay, K
    Aegerter, P
    Bouhassira, M
    Meshaka, P
    Guidet, B
    [J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2006, 22 (01) : 101 - 108
  • [9] Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom
    Green, C
    Dinnes, J
    Takeda, AL
    Cuthbertson, BH
    [J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2006, 22 (01) : 90 - 100
  • [10] Drotrecogin alfa (activated) in severe sepsis: A systematic review and new cost-effectiveness analysis
    Costa V.
    Brophy J.M.
    [J]. BMC Anesthesiology, 7 (1)
12345